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ABSTRACT
Spinal cord injury (SCI) is an injury to the spinal
cord that leads to varying degrees ofmotor and/or
sensory deficits and paralysis. Chronic pain of
both neuropathic and nociceptive type is
common and contributes to reduced quality of
life. The aim of the review is to provide current
clinical understanding as well as discuss and
evaluate efficacy of pharmacological
interventions demonstrated in the clinical
studies. The review was based on literature
search in PubMed and Medline with words
‘‘neuropathic pain’’ and ‘‘spinal cord injury’’. The
review included clinical studies and not
experimental data nor case reports. A limited
number of randomized and placebo-controlled
studies concerning treatment options of
neuropathic pain after SCI were identified.
Amitriptyline, a tricyclic antidepressant and the
antiepileptic drugs, gabapentin and pregabalin,
are most studied with demonstrated efficacy, and
considered tobe theprimary choice.Opioidshave
demonstrated conflicting results in the clinical
studies. In addition, administration route used in
the studies as well as reported side effects restrict
everyday use of opioids as well as ketamine and
lidocaine. Topical applications of capsaicin or
lidocaine as well as intradermal injections of
Botulinum toxin are new treatment modalities
that are so far not studied on SCI population and
need further studies. Non-pharmacological
approaches may have additional effect on
neuropathic pain. Management of pain should
always be preceded by thorough clinical
assessment of the type of pain. Patients need a
follow-up to evaluate individual effect of applied
measures. However, the applied management
does not necessarily achieve satisfactory pain
reduction. Further clinical studies are needed to
evaluate the effect of both established and novel
management options.
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INTRODUCTION
A spinal cord injury (SCI) is an injury to the
spinal cord that leads to varying degrees of
motor and/or sensory deficits and paralysis [1].
Although injury of the cauda equina is
included, the definition excludes isolated
injuries to other nerve roots [2]. The condition
may lead to lifelong loss of function, autonomic
disturbances and reduced quality of life, as well
as increased morbidity and mortality.
Pain is common in patients with SCI [3–5].
The pain may be of nociceptive or neuropathic
type or a combination of the two. Neuropathic
pain following SCI is caused by damage to or
dysfunction of the nervous system, while
nociceptive pain is caused by damage to non-
neural tissue either musculoskeletal due to
bone, joint, muscle trauma or inflammation,
mechanical instability or muscle spasm. Pain of
visceral origin may develop for instance due to
renal calculus, bowel, sphincter dysfunction,
headache related to autonomic dysreflexia and
secondary overuse syndromes [6, 7].
The pain may be localized above, at or below
the level of the SCI and may persist for many
years after the acute injury [8–10]. Pain may
occur immediately after the acute injury or
develop and increase in intensity a long time
after the injury [8, 11]. Neuropathic pain is
found to contribute to reduce quality of life in
patients with SCI [8, 11].
Current review is based on search in PubMed
and Medline databases with words ‘‘neuropathic
pain’’ and ‘‘spinal cord injury’’. The review
included all clinical studies, but not
experimental and case reports, published until
December 2015 when the search was
conducted. The review included all clinical
studies, but not experimental data nor case
reports.
The aim is to provide current clinical
understanding as well as possible treatment
options and initiatives with efficacy evaluation.
This review article is based on previously
conducted studies, and does not involve any
new studies of human or animal subjects




There are large variations in incidence,
prevalence, gender distribution, mechanisms,
level and completeness of SCI worldwide [12–
19].
The global incidence of traumatic SCI is
estimated to be 23 cases per 1,000,000 persons
in 2007 and is dependent on regional results
[20]. The reported annual incidence ranges from
2.3 per million in one Canadian study to 83 per
million in a study from Alaska [18–21].
Differences in definition, inclusion criteria,
classification and procedures for identification
of patients as well as geographical and cultural
issues may contribute to a vast range of annual
incidence reported in the studies [16, 21].
Information about prevalence of traumatic
SCI is scarce [18]. The lowest reported
prevalence is from India, 236 per million
population [22], and the highest from the
USA, 4187 per million population [23]. The
incidence and prevalence of non-traumatic SCI
are very limited and the results are uncertain.
Neuropathic pain is a common complication
following SCI. The prevalence of pain in SCI is
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reported between 18% and 96%, the variation
may be explained by differences in selection of
study populations [4, 24]. Pain is usually
described as present in 60–69% of the SCI
population [5]. Most individuals with chronic
pain and SCI report more than one pain
problem [24]. Prevalence of chronic pain in
individuals with SCI is reported to be 11–94%,
and severe, disabling pain in 18–63% [24].
Clinical Characteristics of Neuropathic
Pain Following SCI
Neuropathic pain above the level of injury is
often caused by concomitant compressive
radiculopathies or sometimes by complex
regional pain syndromes. Neuropathic pain at
the level of injury is caused by nerve-root
compression development of complications
such as syringomyelia or SCI itself, while
neuropathic pain below the level of injury is
caused by spinal cord trauma or disease [2].
A recent prospective study followed 90
patients with traumatic SCI 1, 6 and
12 months after the injury [7]. Eighty-eight
patients completed the 12-month follow-up.
Approximately, 80% of the patients reported
any type of pain at all periods evaluated.
Neuropathic pain related to SCI increased over
time, and musculoskeletal pain decreased
slightly, with both being present in 59% of
patients at 12 months; other neuropathic pain
not related to SCI and visceral pain were present
in 1–3%. Early sensory changes (particularly
cold-evoked dysesthesia) indicated
development of neuropathic pain below the
level of injury later [7]. The findings
demonstrate that examination of sensation
may give additional information about
prognosis. Trauma in the spinal cord may
result in subsequent central neuropathic pain
with localization at or below the level of SCI
with allodynia, hyperalgesia and sensory deficit
in the pain area [25]. There is usually no relation
to movement in neuropathic pain. Different
descriptive words indicating neuropathic
characteristics of sensation such as burning,
tingling, pricking, sharpness, shooting,
squeezing, cold, electric or shock-like pain
have been used by patients [25]. Neuropathic
pain at injury level resolved later in 45% of
patients and below injury-level pain resolved in
33% of cases. The findings indicate that
majority of SCI patients with pain syndromes




Neuropathic pain is defined as proposed by the
International Association for the Study of Pain
(IASP) as ‘‘pain initiated or caused by a primary
lesion or dysfunction of the nervous system’’
[25]. Neuropathic pain is divided into
peripheral and central pain [25–27]. Pain after
SCI is classified according to type, localization
and level of injury [8].
A typical feature of central neuropathic pain
following SCI is its localization below the level
of the injury combined with sensory
phenomena such as allodynia or hyperalgesia
in the painful area [8, 9]. Central neuropathic
pain may develop months or years after the
injury [8–10]. Development of neuropathic pain
a long time after SCI may be a sign of post-
traumatic syringomyelia [8].
Neuropathic pain above the level of injury is
usually not due to the SCI itself. Patients who
use a manual wheelchair may experience carpal
tunnel syndrome and peripheral neuropathic
pain as a result and shoulder pain due to
muscular overuse [28, 29]. Peripheral
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neuropathic pain at injury level can be due to
concomitant injury to the nerve root.
Both nociceptive and neuropathic pain may
vary in intensity and may be dependent on
daily activities as well as being affected by the
individual’s psychosocial environment [30].
PATHOPHYSIOLOGY
Numerous and complex changes in the nervous
system will take place after development of pain
following SCI.
A number of molecular changes will occur
after SCI including changes in sodium ion-
channels, voltage-gated calcium channels,
glutamate and gamma-aminobutyric acid
metabolism, serotonergic, noradrenergic, N-
methyl-D-aspartate (NMDA) and opioid
receptors. Drugs such as antiepileptics, tricyclic
antidepressants and opioids have an effect on
these changes [8, 31]. Neuroplasticity may
contribute to both recovery of neuropathic
pain and maintenance and chronification of
pain after SCI despite for attempts on medical
treatment [31].
Neuropathic pain may also develop because
of compression of nerve roots after spinal
trauma [31, 32]. Clinically, this pain will often
be localized above the level of injury [31].
CLINICAL EXAMINATION
A thorough examination is important to
identify any possible somatic cause of the pain
other than SCI and to classify the type of pain to
optimize therapy. The localization, duration,
intensity and characteristics of pain are useful
information when assessing the pain [8, 32].
The clinical examination must include a
neurological status with a mapping of sensory
phenomena in the painful area, indicating the
presence of neuropathic pain [32]. It is
important to collect data regarding previous
surgical and medical treatment [8]. Information
will help to find possible underlying causes,
classify pain type and relate localization to
previous SCI correctly as well as choose
appropriate modalities of further management.
Pain intensity can be assessed using a visual
analog scale (VAS) or numeric rating scales [8,
33]. Pain characteristics can be mapped using
descriptive scales, such as the McGill Pain
Questionnaire [34]. The International Spinal
Cord Injury Pain Basic Data Set represents an
international consensus on clinical data and
relevant assessments scales required for pain
assessment in SCI patients [35].
TREATMENT
Established Pharmacological Treatment
Neuropathic pain after SCI often emerges as a
chronic condition and responds poorly to a
single drug. However, monotherapy will help
to identify effectiveness of a single drug.
Information about expected effect, the
timeline of treatment and need for follow-up
should be clearly explained to patients.
Freedom from pain is often not realistic,
instead modulation of the neuropathic pain
may be a more achievable goal.
Pharmacological treatment of neuropathic
pain following SCI is in general long-lasting
process and both expected effect and side
effects should be considered before the start
and during follow-up. Table 1 gives an
overview of randomized clinical studies
performed on patients with neuropathic pain
following SCI.
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Antidepressants
Amitriptyline, a tricyclic antidepressant showed
effect in one study [36], while another
randomized study did not confirm this effect
[36, 37]. The applied doses varied between 10
and 150 mg in these studies and the studies
were designed differently and direct comparison
is not possible between these studies. Known
adverse effects such as dry mouth, drowsiness or
tiredness, constipation, urinary retention and
increased spasticity were reported in both
studies [36, 37]. Side effect occurred more
frequently in the study applying higher doses
of amitriptyline [36].
Another antidepressive drug, lithium, has
shown favorable effect on neuropathic pain in a
placebo-controlled study exploring possible
effect on patients with SCI [38]. Oral lithium
was titrated to 0.6–1.2 mmol/l for 6 weeks with
subsequently 6-month clinical follow-up. The
effect of lithium on neuropathic pain was a
secondary outcome in this study. A total of 40
patients were enrolled, half of patients suffered
from severe neuropathic pain. Significant
improvement, measured by visual analog scale
(VAS) was recorded after 6 weeks as well as after
discontinuation of the 6 months of treatment
[38]. However, further studies on neuropathic
pain following SCI are needed to confirm the
effectiveness of lithium.
Two oral antidepressives, trazodone
(50–150 mg) and duloxetine (60–120 mg) have
been studied in the randomized, placebo-
controlled double-blinded studies without
showing any effect in patients with SCI [39, 40].
Other tricyclic antidepressants such as
nortriptyline, imipramine, and desipramine
are considered to be first-line choice in
management of neuropathic pain in general
[41, 42]. Other recommended drugs for
neuropathic pain include venlafaxine, selective
serotonin reuptake inhibitors such as sertraline,
paroxetine, fluoxetine and citalopram [41]. All
these drugs are not, however, sufficiently
studied neither in patients with SCI nor in
patients with neuropathic pain [41]. In
individual intractable cases, both well-
documented and less documented medication
may be considered.
Antiepileptics
Pregabalin and gabapentin are the most studied
drugs against neuropathic pain following SCI.
The analgesic effect of these drugs has been
explained by action through multiple pathways
[32]. Several studies have reported on the
efficacy of gabapentin. [36, 43–47]. Two
studies, including only 27 patients all
together, showed better effect than placebo,
while two other studies showed conflicting
results [36, 43–47]. The administered doses
varied between 300 and 3600 mg. Pregabalin
have been studied in three randomized placebo-
controlled studies in the doses between 150 and
600 mg [48–50]. These studies showed that
pregabalin has superior effect to placebo [48,
49]. Both pregabalin and gabapentin have
similar adverse effect with somnolence,
dizziness, edema, dry mouth, and fatigue [36,
50, 51].
Lamotrigine was studied using doses of
200–400 mg in patients with SCI [52]. Thirty
patients with complete and incomplete injury
were included in the study. Lamotrigine showed
effect on neuropathic pain in the group with
incomplete injury [52]. Levetiracetam and
sodium valproate have been studied in
randomized placebo controlled manner in
patients with SCI [53, 54]. There was, however,
no significant effect on neuropathic pain
recorded in these studies. Carbamazepine has
been studied in one placebo controlled study on
SCI patients. Carbamazepine was administered
up to 600 mg daily to SCI patients without pain.
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The conclusion was that carbamazepine may
prevent the early, but not the long-term
development of neuropathic pain [55]. Other
antiepileptic drugs suggested to have effect
on neuropathic pain are phenytoin,
oxcarbamazepine and lacosamide. However,
the evidence of effect is weak or limited to the
specific types of syndromes with neuropathic
pain and is not studied on patients with SCI
[56]. Phenytoin has been effective on trigeminal
neuralgia in doses 15 mg/kg. Also,
oxcarbamazepine has reduced significantly the
neuropathic pain in doses above 770 mg daily
and lacosamide has proven efficacy in doses
15 mg/kg [56]. Gabapentin and pregabalin
obviously should be used before other
antiepileptics in the SCI-related neuropathic
pain. Other studied antiepileptics may be
considered in individual cases with intractable
neuropathic pain as a last resort.
Opioids
Opioids are potent drugs and recommended as a
medication against intractable pain after SCI
[32, 56, 57]. Tramadol has been shown to be
effective in the randomized placebo-controlled
study on 35 patients with SCI-related
neuropathic pain [58].
Intravenously given morphine did not show
effect in a crossover study in patients with
neuropathic pain due to different conditions
including SCI [59]. Clonidine together with
morphine given intrathecally has been used in
two studies including in total of 23 participants
[60, 61]. Both studies concluded favorable effect
of treatment [60, 61].
The use of Oxycodone, an oral opioid has
demonstrated additional improvement of pain
in patients with SCI and neuropathic pain pre-
treated with antiepileptic drugs [62]. Use of
opioids alone or with other medications may be
an option. However, side effects such as
constipation, nausea and cognitive deprivation
along with the risk of drug abuse may
complicate a long-term use.
Other Anti-Analgesics
Intravenous lidocaine has shown effect on the
patients with SCI and neuropathic pain in a
limited study [63]. A per oral analog to
lidocaine, mexiletine was, however, not
effective in another 4-week placebo-controlled
randomized study where only 11 patients
completed the study [64].
Ketamine, a NMDA receptor antagonist, was
compared with other drugs in three studies [63,
65, 66]. Intravenous ketamine together with
oral gabapentin showed better effect than
gabapentin and placebo immediately after
administration [65]. However, the effect was
not present 2 weeks after treatment. Another
study compared the effect of ketamine (in dose
0.4 mg/kg) with lidocaine (2.5 mg/kg) and
placebo. Ketamine, but not lidocaine, showed
significant effect [67]. The third study
investigated the effect of ketamine together
with l-receptor agonist alfentanil compared
with placebo [66]. This study showed
significant effect in patients with SCI and
neuropathic pain with dysesthesia.
Intravenously administered lidocaine in
dosage 5 mg/kg has also shown effect [63].
However, daily intravenous administration will
limit the use of these medications on patients
with long-lasting pain.
Cannabis-based medications have been
studied both in patients with neuropathic pain
and also in patients suffering from spasticity
related pain in particular. A pilot study on
Dronabinol, oral cannabinoid given 5–20 mg
daily to patients with SCI and neuropathic pain
did not show better effect than placebo [68].
Two studies using cannabis spray on a mixed
cohort including patients with SCI
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demonstrated significant effect on neuropathic
pain [69, 70]. The studies are so far too limited
and efficacy of cannabinoids and opioids is
questionable.
Treatment of neuropathic pain after SCI may
include use of topical agents [71]. Topical use of
0.025% capsaicin ointments was studied in a
retrospective study including only eight
patients, proved effective on neuropathic pain
[72]. Topical use of lidocaine or high doses of
capsaicin (8%) has not been studied on patients
with SCI. These drugs have, however, shown
effect on the other types of neuropathic pains
[56, 73]. Another new approach for treatment of
well-localized neuropathic pain is intradermal
use of botulinum toxin A injections [73]. This
treatment has not been tried on SCI-related
neuropathic pain, but it proved effective in the
cases with chronic neuropathic pain after
surgery or trauma [74]. The treatment should
be studied further on patients with SCI-related
neuropathic pain in future.
A recent systematic review compared all
available pharmacologic therapies for
neuropathic pain following SCI and concluded
that available studies are small and cause
insufficient data for quantitative comparisons
[75].
Other Options of Treatment
of Neuropathic Pain Following SCI
Two studies examined the effect of
transcutaneous electrical nerve stimulation
(TENS) on neuropathic pain following SCI [76,
77]. Low-frequency TENS demonstrated a
favorable effect on pain [77]. Transcranial
electric stimulation either alone or together
with visual illusions was studied in several
studies [78–81]. Favorable effect was
demonstrated in all studies. One observational
study exploring the effect of visual illusions
demonstrated significant reduction of pain as
measured by VAS [82]. Transcranial magnetic
stimulation did not however show significant
effect in two studies on SCI patients [83, 84].
One study, exploring effect of deep brain
stimulation did not demonstrate effect of such
procedure [85].
Two studies, one of them a mixed cohort,
have shown partial effect of DREZotomy (Dorsal
Root Entry Zone—a surgical treatment) on
neuropathic pain [86, 87].
One observational study investigated the
effect of acupuncture or massage on
neuropathic pain following SCI [88].
Comparing pain before and after treatment,
reduction of pain was reported with both
acupuncture and massage. Osteopathic
manipulation did not however show any effect
in SCI patients with neuropathic pain [89].
Management of Both Neuropathic Pain
and Nociceptive Pain
Both nociceptive and neuropathic pain may
occur simultaneously in patients with SCI.
Given this, management of both types of pain
should be addressed. The effect of single pain
medication or combinations against mixed
types of pain after SCI has not been
systematically studied. Non-steroidal anti-
inflammatory drugs and opioid medication is
widely clinically used [90]. Acupuncture,
manual therapy, hypnosis and biofeedback
have demonstrated effect on nociceptive pain
and should be considered as possible options of
non-pharmacological treatment in the cases
with mixed pain [91–93]. Physiotherapy can
alleviate nociceptive pain and should be
considered, particularly if muscular shoulder
pain is present [94–96].
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RECOMMENDATIONS
Based on current knowledge, amitriptyline,
gabapentin and pregabalin have the best
documented effects on neuropathic pain after
SCI and should be considered as the first choice.
However, the documentation about efficacy is
limited on patients with SCI-related pain in
most other options and individual variations in
response to treatment are observed. In addition,
side effects should be considered, particularly if
high doses are used. The available clinical trials
demonstrate that use of higher doses results in
several and more serious side effects. In the
cases of intractable pain, treatments effective on
other types of neuropathic pain may be
considered. A combination of several drugs or
measures, although scarcely studied so far, has
probably more pronounced effect than
administration of one single drug.
Maintenance of treatment effect is not
systematically studied. Therefore, the patients
should be followed up and treatment should be
evaluated continuously. Further studies are
needed for evaluation of efficacy of those
measures on pain after SCI.
CONCLUSIONS
The majority of patients suffer from pain
following SCI. Pain has profound impact on
many aspects of daily life. The management of
pain should be based on clinical findings
leading to diagnosis of pain type and
evaluation of effect of treatment. Thorough
clinical assessment of the condition should
precede administration of drugs to make sure
of the presence of neuropathic pain.
Evidence of efficacy of pharmacological
treatment of neuropathic pain following SCI is
limited and available literature does not give
enough information about long-term effect or
usefulness of combination therapy. Based on
current knowledge, tricyclic antidepressant
amitriptyline and antiepileptics gabapentin
and pregabalin have the best documented
effect on neuropathic pain after SCI.
Treatment of topical agents such as capsaicin
or lidocaine as well as with intradermal
Botulinum toxin injections may be useful
approaches but need to be studied on
populations with SCI. Further studies are
needed for evaluation of efficacy of those
measures on pain after SCI.
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